Dayvigo
Drug
Eisai Inc.
Total Payments
$8.7M
Transactions
87,410
Doctors
29,242
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $454,562 | 32 | 4 |
| 2023 | $413,649 | 111 | 45 |
| 2022 | $1.1M | 7,193 | 5,501 |
| 2021 | $4.2M | 55,329 | 23,386 |
| 2020 | $2.5M | 24,745 | 10,784 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 386 | 53.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 2,186 | 19.1% |
| Food and Beverage | $1.5M | 83,821 | 17.0% |
| Consulting Fee | $787,439 | 317 | 9.1% |
| Travel and Lodging | $100,465 | 436 | 1.2% |
| Grant | $15,000 | 1 | 0.2% |
| Education | $2,142 | 262 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $2,000 | 1 | 0.0% |
Payments by Type
Research
$4.6M
386 transactions
General
$4.0M
87,024 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Subjects With Moderate to Severe Obstructive Sleep Apnea and Adult and Elderly Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | Eisai Inc. | $2.0M | 0 |
| Research Collaboration | Eisai Inc. | $622,683 | 0 |
| An Open-label, Parallel-Group Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects | Eisai Inc. | $530,299 | 0 |
| Lemborexant in Delayed Sleep Phase Syndrome | Eisai Inc. | $324,620 | 0 |
| Analysis of sleep EEG data for insomnia patients on lemborexant, zolpidem, or placebo | Eisai Inc. | $300,000 | 0 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia | Eisai Inc. | $256,423 | 0 |
| HAND IPT/Lemborexant | Eisai Inc. | $251,000 | 0 |
| Effects of Lemborexant vs placebo on total daytime sleep in shift workers: A randomized controlled trial | EISAI INC. | $105,374 | 0 |
| Lemborexant Effects on Morning-After Neurocognition Study (LE MANS) | Eisai Inc. | $103,939 | 0 |
| A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder | Eisai Inc. | $78,654 | 0 |
| Effects of Lemborexant vs placebo on total daytime sleep in shift workers: A randomized controlled trial | Eisai Inc. | $68,784 | 0 |
| A Prospective, Non-Interventional Study to Determine Signs and Symptoms That Impact Daily Life of Patients With Irregular Sleep-Wake Rhythm Disorder and Their Caregivers | Eisai Inc. | $28,275 | 0 |
| Lemborexant Effects on Morning-After Neurocognition Study (LE MANS) | EISAI INC. | $11,612 | 0 |
| A prospective, non-interventional study to assess the content validity, electronic usability and feasibility of a novel observer-reported outcome measure in irregular sleep-wake rhythm disorder. | Eisai Inc. | $1,040 | 0 |
Top Doctors Receiving Payments for Dayvigo
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Wichita, KS | $4.7M | 388 |
| , MD, MPH | Psychiatry | Pomona, NY | $219,801 | 121 |
| , MD | Sleep Medicine | Mobile, AL | $139,297 | 239 |
| , MD | Psychiatry | Lake Jackson, TX | $133,626 | 158 |
| , M.D | Psychiatry | Huntersville, NC | $122,193 | 172 |
| , MD | Internal Medicine | Pacific Palisades, CA | $111,564 | 249 |
| , M.D | Psychiatry | Saint Charles, MO | $66,178 | 77 |
| , MD | Family Medicine | Collegeville, PA | $62,602 | 97 |
| , MD | Psychiatry | Plano, TX | $53,187 | 134 |
| , MD | Neurology | Chicago, IL | $48,432 | 15 |
| , M.D | Pulmonary Disease | Columbia, SC | $43,932 | 65 |
| , MD | Internal Medicine | Cromwell, CT | $42,490 | 82 |
| , MD | Sleep Medicine | Los Angeles, CA | $37,587 | 34 |
| , M.D | Sleep Medicine | Willow Grove, PA | $32,920 | 38 |
| , M.D | Psychiatry | Roanoke, VA | $32,900 | 53 |
| , M.D | Psychiatry | Dallas, TX | $32,613 | 84 |
| , M.D | Psychiatry | Costa Mesa, CA | $30,932 | 57 |
| , M.D | Psychiatry | Durham, NC | $30,654 | 18 |
| , M.D | Addiction Psychiatry | Dallas, TX | $29,796 | 63 |
| , MD | Psychiatry | Moosic, PA | $28,941 | 63 |
| , M.D | Psychiatry | Longview, TX | $27,291 | 55 |
| , M.D | Psychiatry | Ridgeland, MS | $26,514 | 59 |
| , MD | Psychiatry | Decatur, GA | $26,354 | 66 |
| , M.D | Neurology | Richmond, KY | $25,394 | 32 |
| , MD | Psychiatry | Tampa, FL | $23,900 | 27 |
Ad
Manufacturing Companies
- Eisai Inc. $8.1M
- EISAI INC. $486,436
- Eisai Co., Ltd. $39,873
Product Information
- Type Drug
- Total Payments $8.7M
- Total Doctors 29,242
- Transactions 87,410
About Dayvigo
Dayvigo is a drug associated with $8.7M in payments to 29,242 healthcare providers, recorded across 87,410 transactions in the CMS Open Payments database. The primary manufacturer is Eisai Inc..
Payment data is available from 2020 to 2024. In 2024, $454,562 was paid across 32 transactions to 4 doctors.
The most common payment nature for Dayvigo is "Unspecified" ($4.6M, 53.5% of total).
Dayvigo is associated with 14 research studies, including "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Subjects With Moderate to Severe Obstructive Sleep Apnea and Adult and Elderly Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease" ($2.0M).